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Results: BI 2536 potently inhibited proliferation of NSCLC cell lines 
with EC50 values of 8 - 14 nM. The compound showed good anti-tu-
mor activity in vivo in all 4 NSCLC xenograft models tested with T/C 
(“treated/control”) values of 1% (Calu-6), 14% (A549), 21% (NCI-
H460), and 41% (NCI-H520TC) at doses that were well tolerated. Im-
munohistochemical analysis of NCI-H460 tumors excised from treated 
animals as well as near-infrared optical imaging using Cy5.5-coupled 
annexin V demonstrated mitotic arrest and induction of apoptosis in 
vivo. Combination therapy with established chemotherapeutic agents 
(cisplatin, docetaxel or pemetrexed) resulted in improved efﬁcacy in 
the absence of additional toxicity. 
Conclusion: BI 2536 is a potent inhibitor of NSCLC cell prolifera-
tion in vitro and shows efﬁcacy in multiple human NSCLC xenograft 
models at well-tolerated doses. Combination therapy with BI 2536 and 
established chemotherapeutic agents is well tolerated and results in 
improved efﬁcacy compared to single-agent treatment. 
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Background: ING genes (Inhibitor of Growth, ING1-5) are candidate 
tumor suppressor genes which have been recently identiﬁed and charac-
terized. Whereas ING1 expression has been shown to be down-regulat-
ed in several tumor types through a yet unknown mechanism (mutation 
of the gene is a rare event), few data have been reported regarding the 
status of other members of the family. ING2 is involved in tumor sup-
pression pathways such as apoptosis and senescence. It is a chromatin 
associated protein, a nuclear phosphoinositide receptor which interacts 
with trimethylated H3 on lysine 4 and can regulate p53 transcriptional 
activity by enhancing its acetylation to modulate cellular response to 
genotoxic stress. ING2 status in human tumors is still unknown (one 
study reported the reduced expression of ING2 in melanoma) and its 
role and regulation in carcinogenesis are poorly understood.
Methods: We investigated the involvement of ING2 in human lung 
tumors by analyzing ING2 protein expression on tumors and their 
related normal tissues (this study was done on samples from the tumor 
bank (CRB, Grenoble) and with tumor tissue micro-arrays. Immunohis-
tochemical analysis was performed on 75 formalin ﬁxed tumor tissues 
and normal counterpart using speciﬁc ING2 polyclonal antibody KMP1 
(kindly provided by Dr. C. Harris) dilution 1/100. Score of immunos-
taining (0-300) was established by multiplicating the percentage of 
stained cells (0-100) by intensity (1-3). Cut-off of score for discrimi-
nating positive from low expression and negative was determined by 
the mean level of expression on normal alveolar cells taken as internal 
control (mean 120): score of 0 to 50 considered as negative; 50 to 
120 as low and >120 as positive. mRNA were extracted by Trizol and 
analyzed by RT-PCR.
Results: A strong and mainly (but not exclusively) nuclear staining of 
ING2 was detected in normal lung tissues, mostly in Type II pneu-
mocytes. In non-small cell lung cancers, a loss or low level of ING2 
expression was observed in 75 % (27/36) adenocarcinoma and 82 % 
(32/39) squamous cell carcinoma as compared with normal lung. Fur-
thermore, in many cases, the ING2 nuclear staining was lost; whereas, 
the cytoplasmic staining was maintained. These results suggest that 
in tumor cells ING2 could be excluded from the nucleus. Analysis of 
mRNA expression by real-time PCR of 13 tumors and corresponding 
normal lung tissues showed a marked decrease of the mRNA in tumors. 
Since ING2 promoter contains several CpG islands, methylation of the 
promoter in these tumors is being investigated.
Conclusion: Taken together, these results suggest that ING2 could be 
inactivated in lung tumors either by downregulation at the mRNA level 
or exclusion of the protein from the nucleus. Further analysis of these 
tumors, especially their p53 status should help us to understand the role 
ING2 could play in lung carcinogenesis.
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Background: Radiation dose escalation might improve local control 
in NSCLC, but is associated with increased toxicity. Consequently 
patients have to be selected carefully to prevent, both over- and under-
treatment. As part of a prospective clinical trial we reported that meta-
bolic responders and non-responders (EORTC-criteria) showed differ-
ent time trends in maximal SUV (standardized uptake value, SUVmax) 
of 18F-FDG on PET-scan. Moreover, metabolic responders showed an 
improved overall survival compared to non-responders (van Baard-
wijk et al., Radioth Oncol 2007). The aim of the current study was to 
investigate changes in plasma levels of cytokines and the association 
of these changes with SUVmax and the amount of toxicity during and 
after radiotherapy (RT), to further unravel underlying mechanisms.
Methods: From 21 patients included in the clinical trial, repeated 
plasma samples (n=67) were collected before RT, on day 7 and 14 
during RT and 70 days after RT. Levels of IL-1b, IL-5, IL-6, IL-8, 
IL-10, TNF-α, M30, M65, osteopontin and neopterin were assessed 
using ELISA’s. Unmeasurable levels were assumed to be zero. Levels 
of cytokines were associated with SUVmax of FDG-PET and toxicity 
score, according to CTCAE-criteria. Moreover, changes in levels of 
cytokines between the different time points during RT (day 0 versus 
day 7, day 7 versus day 14) were correlated with changes in SUVmax 
within the same time-interval. Results are expressed as mean ± SEM. 
Pearson correlation coefﬁcient and Mann Whitney U-test were used to 
analyze the data. 
Results: A large heterogeneity in evolution in cytokine levels during 
RT was observed between individual patients. It was shown that chang-
es in SUVmax correlated with changes in the level of IL-6, showing a 
